Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

And anyone who suffers from myasthenia gravis, however mild it is, should be monitored, in particular with the eye muscle weakness or the eyelid weakness that occurs. It's important that any ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Nowak, MD, director of the Myasthenia Gravis Clinic at Yale University ... “About 15% and maybe up to 20% have medically refractory or inadequately controlled disease,” he said.

Generalized myasthenia gravis (gMG) affects most patients through ... stem cell transplantation is also being evaluated in ...

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...